In Situ Formed ROS‐Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.
- Resource Type
- Article
- Source
- Advanced Healthcare Materials; 8/8/2023, Vol. 12 Issue 20, p1-12, 12p
- Subject
- Language
- ISSN
- 21922640